BIOINVEST BREAKING NEWS – Special Update – ANTH — As IgAN Data Nears, The Case For A Reduction In Proteinuria. With Anthera shortly delivering its first new clinical trial results in a long time, the implications of the IgAN data, in our opinion the implications of the IgAN data, while not yet valued by investors, are many. Read more…